Factors influencing fetal cardiac conduction in anti-Ro/SSA-positive pregnancies

  title={Factors influencing fetal cardiac conduction in anti-Ro/SSA-positive pregnancies},
  author={Sven‐Erik Sonesson and Malin Hedlund and Aur{\'e}lie Ambrosi and Marie Wahren-Herlenius},
Objectives Congenital heart block (CHB) develops in 1-2% of anti-Ro/SSA-positive pregnancies and has a recurrence rate of 12-20%, which indicates that factors other than maternal autoantibodies are crucial for CHB to occur. Here, we aimed to evaluate the influence of factors previously associated with CHB on the occurrence of milder forms of fetal cardiac conduction disturbances, shown to occur in up to 30% of anti-Ro/SSA-positive pregnancies, and on neonatal outcome in a large cohort of… 

Figures and Tables from this paper

Risk factors for autoimmune-mediated congenital heart block
The data expands the current understanding of CHB pathogenesis, and suggests that the overall fetal susceptibility to CHB and degree of disease severity depends on a combination of genetic risk variants, their overall functional consequences, and their interactions with intrauterine factors in addition to the effect of fetal exposure to maternal Ro/SSA autoantibodies.
Autoimmune congenital heart block and primary Sjögren's syndrome: characterisation and outcomes of 49 cases.
In pSS, autoimmune CHB could be one of the first "indirect" signs of the disease in women of childbearing-age, in whom the diagnosis is confirmed several years later.
Interferons and innate immune activation in autoimmune congenital heart block
An update on the epidemiology, clinical presentation and current treatment approaches of autoimmune CHB is provided, the previously proposed pathogenic mechanisms implicating maternal autoantibodies are summarized, and the recent findings of type I interferon (IFN) and innate immune activation in foetuses with autoimmuneCHB and in neonates of anti‐Ro/La antibody‐positive mothers are discussed.
Congenital atrioventricular heart block: From diagnosis to treatment
Benefits of fetal echocardiographic surveillance in pregnancies at risk of congenital heart block: single‐center study of 212 anti‐Ro52‐positive pregnancies
A surveillance program for at‐risk pregnancies is introduced with the dual aim of investigating if fetal atrioventricular block could be detected and treated before becoming complete and irreversible, and to establish the incidence of AVB I, II and III in a large prospective cohort.
Bench to bedside review of myositis autoantibodies
This review is intended to highlight the comprehensive scenario regarding myositis-related autoantibodies from the molecular characterization and biological significance to target antigens, from the detection tools, with a special focus on immunofluorescence patterns on HEp-2 cells, to their relative prevalence and ethnic diversity from the clinical presentation to prognosis.


Development of heart block in children of SSA/SSB-autoantibody-positive women is associated with maternal age and displays a season-of-birth pattern
Maternal age and seasonal timing of pregnancy are identified as novel risk factors for heart block development in children of Ro/La-positive women and these observations may be useful for counselling when pregnancy is considered.
Signs of first-degree heart block occur in one-third of fetuses of pregnant women with anti-SSA/Ro 52-kd antibodies.
Serial Doppler echocardiographic measurement of AV time intervals is suggested as a useful method for surveillance of high-risk pregnant women with anti-SSA/Ro 52-kd antibodies.
Risk of congenital complete heart block in newborns of mothers with anti-Ro/SSA antibodies detected by counterimmunoelectrophoresis: a prospective study of 100 women.
The prevalence of CCHB in newborns of prospectively followed up women already known to be anti-Ro/SSA positive and with known CTD was 2%.
Outcome of pregnancies in patients with anti-SSA/Ro antibodies: a study of 165 pregnancies, with special focus on electrocardiographic variations in the children and comparison with a control group.
The results suggest that the prolongation of the QTc interval and sinus bradycardia that have recently been reported in children of mothers with anti-SSA antibodies occur independently of the anti- SSA antibodies.
Recurrence rates of cardiac manifestations associated with neonatal lupus and maternal/fetal risk factors.
The recurrence rate of cardiac NL appeared to be unaffected by maternal health, use of steroids, antibody status, severity of cardiac disease in the first affected child, or sex of the subsequent child.
Maternal predictive factors for fetal congenital heart block in pregnant mothers positive for anti-SS-A antibodies
The results identified high titers of anti-SS-A antibodies and use of corticosteroids before conception as independent risk factors, andUse of cortiosteroids after conception before 16-week gestation as an independent protective factor for fetal CHB.
Birth order, gender and recurrence rate in autoantibody-associated congenital heart block: implications for pathogenesis and family counseling.
In the present analysis, the focus was only on CHB and not other manifestations of neonatal lupus such as skin or liver disease, because these are often evanescent and ascertainment by clinicians is likely incomplete.
Increased risk of complete congenital heart block in infants born to women with hypothyroidism and anti-Ro and/or anti-La antibodies.
This study indicates that women with hypothyroidism should be tested for anti-Ro antibodies, as they may be at risk to deliver a child with CCHB.